Document is current
Any future updates will be listed below
-
Authors
Ronnacker, Julian
Muller, Philippe J. https://orcid.org/0009-0000-0985-7666
Mikesch, Jan-Henrik
Zukunft, Sven https://orcid.org/0000-0002-1811-4562
Weinbergerová, Barbora https://orcid.org/0000-0001-6460-2471
Šrámek, Jiří https://orcid.org/0000-0003-3303-4146
Valka, Jan https://orcid.org/0000-0002-2248-0557
Novak, Jan
Zak, Pavel
Szotkowski, Tomas
Koristek, Zdenek
Krekeler, Carolin https://orcid.org/0009-0000-1808-5928
Unglaub, Julia M.
Sauer, Tim
Ruhnke, Leo
Kraus, Sabrina
Schaffrath, Judith
Müller, Lutz P. https://orcid.org/0000-0002-2212-8166
Kaes, Sabrina
Niemann, Dirk
Fransecky, Lars
Hess, Patrick P. https://orcid.org/0000-0002-0693-7393
Crysandt, Martina
Jost, Edgar
Millo, Joana
Gaertner, Johannes
Repp, Roland
Jentzsch, Madlen https://orcid.org/0000-0002-2270-0804
Hoppe, Lea
Klein, Stefan
Modemann, Franziska https://orcid.org/0000-0002-5897-3310
Michalowski, Nina
Fischbach, Klaudia
Blau, Wolfgang
Ruhs, Marion
Ritter, Markus
Lohmeyer, Julian
Steffen, Björn https://orcid.org/0009-0002-6693-4079
Hauser, Sarah
Kaufmann, Martin
Krause, Stefan W. https://orcid.org/0000-0002-5259-4651
Knabe, Ricarda
Spiekermann, Karsten https://orcid.org/0000-0002-5139-4957
Serve, Hubert
Platzbecker, Uwe
Baldus, Claudia D. https://orcid.org/0000-0002-0748-834X
Müller-Tidow, Carsten https://orcid.org/0000-0002-7166-5232
Lenz, Georg https://orcid.org/0000-0002-4728-1693
Reinhardt, Hans Christian
Mayer, Jirí
Bornhäuser, Martin
Röllig, Christoph https://orcid.org/0000-0002-3791-0548
Schliemann, Christoph https://orcid.org/0000-0003-1755-9583
Hanoun, Maher https://orcid.org/0000-0002-1754-8940
- License Information
-
More Information
Article History
Received: 3 April 2025
Revised: 19 June 2025
Accepted: 7 July 2025
First Online: 21 July 2025
Competing interests
: TS received honorarium, financial support, and congress participation from Pfizer and served as a consultant for Pfizer. FM received support for meeting attendance from Servier, AbbVie, Incyte, Gilead, Jazz Pharmaceuticals, Novartis, Teva, Pfizer, and Amgen; received support for medical writing from Servier, and Springer Verlag; received research grants from Apis Technologies, and Daiichi Sankyo; received speaker honoraria from Servier, Jazz Pharmaceuticals, Daiichi Sankyo, and AbbVie; participated in advisory boards for Otsuka Pharma, Servier, Pfizer, and Daiichi Sankyo. SK received honorarium as a speaker from Eickeler and travel support from AbbVie, Alexion, and Jazz. KS received speaker honoraria and/or travel grants from and/or has been a consultant to: AbbVie, Alexa, Bristol Myers Squibb, Jazz Pharmaceuticals, Leo, Pfizer, Sanofi, Servier, Sobi, Stemline, Takeda, MSD, Gilead. GL received research grants not related to this manuscript from AGIOS, AQUINOX, AstraZeneca, Bayer, Celgene, Gilead, Janssen, MorphoSys, Novartis, F. Hoffmann-La Roche Ltd, and Verastem. GL received honoraria not related to this study from ADC Therapeutics, AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, BMS, Celgene, Constellation, Genase, Genmab, Gilead, Hexal/Sandoz, Immagene, Incyte, Janssen, Karyopharm, Lilly, Miltenyi, MorphoSys, MSD, NanoString, Novartis, PentixaPharm, Pierre Fabre, F. Hoffmann-La Roche Ltd, and Sobi. HCR received consulting and lecture fees from AbbVie, Roche, KinSea, Vitis, Cerus, Lilly, Novartis, Takeda, AstraZeneca, Vertex, and Merck. HCR received research funding from AstraZeneca and Gilead Pharmaceuticals. HCR is a co-founder of CDL Therapeutics GmbH. MBo has no conflict of interest regarding this work. Outside this study, he has received lecture fees and served on advisory boards for Jazz, MSD, and ActiTrexx. CR has received honoraria from AbbVie, Astellas, Bristol-Meyer-Squibb, Daiichi Sankyo, Jazz, Janssen, Novartis, Otsuka, Pfizer, Servier, and institutional research funding from AbbVie, Astellas, Novartis, Pfizer. CS received honoraria/has served on Advisory Boards for AbbVie, Astellas, AstraZeneca, BMS, Daiichi Sankyo, Laboratories Delbert, Jazz Pharmaceuticals, Novartis, Otsuka, Pfizer, Roche. CS received institutional research support from Jazz Pharmaceuticals and congress/travel grants from AbbVie, BMS, Jazz Pharmaceuticals, and Pfizer.
: All procedures were performed in accordance with the relevant guidelines and regulations. The bio-registry of the SAL (NCT03188874), which encompasses 59 centers specialized in the treatment of hematologic neoplasms across Germany and the Czech Republic, is approved by the ethics committee of the Technical University Dresden (EK 98032010). The registry at the University Hospital Hamburg-Eppendorf is approved by the ethics committee of the Medical Association Hamburg (PV3469). Written informed consent was obtained from all participants.
